Skip to main content
High Bile Acids in Pregnancy

When Itching Becomes a Fetal Risk Signal

Intrahepatic Cholestasis of Pregnancy is often first felt before it appears on a report.

The woman may notice relentless itching.

Her first bile-acid result may still be normal.

Later, the level may rise enough to change the safest timing of birth.

No doctor can guarantee the outcome of a pregnancy.

Expert care can do something more honest and clinically important:

  • Listen to the symptom before dismissing it.
  • Measure the right blood test.
  • Follow the highest bile-acid level.
  • Separate mild disease from severe disease.
  • Use nutrition as active maternal management.
  • Avoid false reassurance from a normal scan or CTG.
  • Plan birth before the risk of remaining pregnant becomes greater than the risk of delivery.

Nutrition is an active part of my management—not an afterthought added after the laboratory report.

My approach begins with three principles:

  • The itch raises the suspicion.
  • Nutrition supports the mother and may improve the biochemical pattern.
  • The peak bile-acid level and timing of birth guide fetal safety.
Schedule a High Bile Acids ConsultationUnderstand the Monitoring Plan
Recognising the Signal

Every Itch Needs a Context

The condition is medically called:

Intrahepatic Cholestasis of Pregnancy, or ICP.

It is also commonly called:

  • IHCP.
  • Obstetric cholestasis.
  • Pregnancy cholestasis.
  • Raised bile acids in pregnancy.

ICP affects the way the liver handles bile during pregnancy.

Bile acids are produced in the liver and normally pass into the intestine, where they help the body digest fats.

In ICP, this process becomes impaired.

Bile acids accumulate in the maternal blood and may cross the placenta.

The most recognisable symptom is itching without a primary skin rash.

The itching may:

  • Affect the palms of the hands.
  • Affect the soles of the feet.
  • Spread over the arms, legs, abdomen or entire body.
  • Become worse at night.
  • Disturb sleep severely.
  • Begin mildly and become intense.
  • Appear before the blood tests become abnormal.

ICP usually develops later in pregnancy.

It can begin earlier.

There May Still Be Marks on the Skin

ICP does not cause a primary rash.

Scratching can cause:

  • Redness.
  • Excoriations.
  • Broken skin.
  • Scabs.
  • Bruising.
  • Secondary infection.

A woman may also have eczema, an allergy or another skin disorder at the same time.

Visible scratch marks do not exclude ICP.

Itching Is Common. ICP Is Not.

Many pregnant women experience itching.

Most do not have ICP.

However, persistent, generalised or nocturnal itching— especially involving the palms or soles—deserves assessment.

The symptom should not be dismissed merely because:

  • There is no jaundice.
  • The first liver-function test is normal.
  • The first bile-acid result is normal.
  • The baby is moving normally.
  • An ultrasound is reassuring.

Some women experience itching for days or weeks before their blood results become abnormal.

If the itching continues, the tests should be repeated.[1–5]

A normal bile-acid result answers the question for the day the blood was taken. It does not permanently exclude ICP.

Symptoms That Need a Broader Assessment

ICP is an important diagnosis.

It is not the only possible cause of itching or abnormal liver tests in pregnancy.

A broader assessment is particularly important when there is:

  • Very early onset.
  • Severe disease early in pregnancy.
  • Fever.
  • Significant abdominal or right-upper-quadrant pain.
  • Persistent vomiting.
  • Jaundice.
  • Dark urine.
  • Pale stools.
  • Loss of appetite.
  • Marked weakness.
  • High blood pressure.
  • Severe headache.
  • Visual disturbance.
  • Rapid swelling.
  • Low platelets.
  • Significant bilirubin elevation.
  • Symptoms continuing after birth.
  • Known liver or gallbladder disease.

These features may indicate another condition or a second condition occurring alongside ICP.

Severity Classification

The Bile Acid Matters More Than the Itch

The severity of itching does not reliably predict the bile-acid level.

A woman with intense itching may have a modest elevation.

Another woman with less dramatic itching may have severe biochemical disease.

The itching deserves treatment.

The bile-acid concentration guides fetal-risk assessment.

Current Severity Categories

Using the RCOG classification based on the highest recorded bile-acid level:

Mild ICP
19–39 µmol/L
Moderate ICP
40–99 µmol/L
Severe ICP
100 µmol/L or more

These categories must be interpreted together with:

  • Gestational age.
  • Singleton or multiple pregnancy.
  • Previous ICP.
  • Previous stillbirth.
  • Pre-eclampsia.
  • Gestational diabetes.
  • Fetal growth concerns.
  • Other maternal medical conditions.
  • The trend in bile-acid results. [1,2]

The Highest Level Matters

Bile acids can fluctuate.

A later result may fall because of:

  • Natural biological variation.
  • Timing of the blood sample.
  • Treatment.
  • Laboratory variation.
  • Changes in food intake.

A fall in the result does not erase the fact that a higher concentration occurred earlier.

Fetal-risk assessment and timing of birth should consider the peak bile-acid concentration during the pregnancy, not only the latest report.[1,4–6]

A falling result can be encouraging. It does not rewrite the pregnancy’s highest-risk category.

Mild ICP: 19–39 µmol/L

In an otherwise uncomplicated singleton pregnancy, the stillbirth risk appears similar to the background pregnancy risk.

This does not mean that the diagnosis should be ignored.

The woman still requires:

  • Repeat bile-acid testing.
  • Review of symptoms.
  • Assessment for associated conditions.
  • An individualised birth plan.
  • Immediate assessment if fetal movements reduce or change.

The bile-acid level may remain mild.

It may also rise later.

Moderate ICP: 40–99 µmol/L

At this level, the risks of the following become more relevant:

  • Spontaneous preterm birth.
  • Meconium-stained amniotic fluid.
  • Neonatal-unit admission.

In an otherwise uncomplicated singleton pregnancy, the stillbirth risk appears similar to background risk until approximately 38–39 weeks.

This is why planned birth is usually discussed before or around that stage rather than routinely waiting beyond it.[1,2,5,6]

Severe ICP: 100 µmol/L or More

This is the level at which the stillbirth risk rises substantially.

RCOG patient information estimates that approximately 3 in 100 women with severe ICP may experience stillbirth after 36 weeks.

Large international data show a marked increase in risk when the peak bile-acid concentration reaches 100 µmol/L or more.

The increase becomes particularly important from approximately 35–36 weeks.

This is why major international guidelines recommend planned preterm or early-term birth rather than routinely waiting until the due date.[1–6]

At 100 µmol/L or more, the conversation changes from routine observation to active prevention through the timing of birth.

Individualising the Plan

The Pattern Matters More Than One Report

Two women may both have a bile-acid result of 45 µmol/L.

They may not require identical care.

Itching With Normal Bile Acids

This may mean:

  • ICP has not developed.
  • The blood was taken before the bile acids rose.
  • Another skin or medical condition is causing the itching.
  • Symptoms require repeat testing.

If itching persists and no other explanation is found, bile acids and liver tests should be repeated.

Treatment should not permanently replace diagnostic confirmation.

Where clinically appropriate, the initial blood sample should be collected before ursodeoxycholic acid is started.

Bile Acids of 19–39 µmol/L Near Term

This often allows a later birth plan than severe ICP.

The decision still depends on:

  • Whether the level remains stable.
  • Other pregnancy complications.
  • Previous history.
  • Fetal movements.
  • Patient preference.

Bile Acids of 40–99 µmol/L

This level requires closer attention to:

  • The biochemical trend.
  • Gestational age.
  • Associated pre-eclampsia or diabetes.
  • Multiple pregnancy.
  • Previous severe ICP.
  • Planned timing of birth.

Bile Acids of 100 µmol/L or More

This level should prompt specialist-led delivery planning.

Waiting for the bile acid to fall before making a plan may create false reassurance.

The peak value remains clinically relevant even if treatment or dietary management lowers a later result.

Severe Disease Before 28 Weeks

Early-onset severe ICP is unusual.

It should prompt consideration of:

  • Underlying liver disease.
  • Gallstones or biliary obstruction.
  • Viral hepatitis.
  • Autoimmune liver disease.
  • Drug-related liver injury.
  • Genetic susceptibility affecting bile transport.
  • Multiple pregnancy or very high hormonal exposure.

Obstetric, fetal-medicine and hepatology input may be required.

A Previous ICP Pregnancy

A previous pregnancy may tell us:

  • How early symptoms began.
  • How high the bile acids became.
  • Whether they rose rapidly.
  • Whether early delivery was required.
  • Whether meconium was present.
  • Whether the baby required neonatal care.
  • Whether a fetal loss occurred.

The current pregnancy should not be managed as though that history does not exist.

ICP With Twins or Triplets

Multiple pregnancy already carries additional maternal and fetal risks.

ICP may begin earlier and may be more severe.

Delivery timing cannot be copied directly from an uncomplicated singleton pregnancy.

ICP With Pre-eclampsia or Gestational Diabetes

Both conditions may alter maternal and fetal risk.

The final plan should address the complete pregnancy—not the bile-acid result in isolation.

The First Consultation

Before Ordering Tests, Reconstruct the Story

The first consultation should not begin and end with the latest laboratory value.

It should reconstruct the symptom, the biochemical pattern, nutrition, maternal health and the complete pregnancy risk.

I review:

  • When the itching began.
  • Where it began.
  • Whether the palms or soles are involved.
  • Whether it is worse at night.
  • Whether there is a primary rash.
  • Whether sleep has become severely disturbed.
  • Whether jaundice is present.
  • Urine and stool colour.
  • Abdominal pain.
  • Nausea or vomiting.
  • Appetite and weight changes.
  • Current medicines and supplements.
  • Antibiotics or hormonal medicines used recently.
  • Previous gallstones.
  • Previous liver disease.
  • Previous hepatitis.
  • Autoimmune disease.
  • Family history of ICP or liver disease.
  • Previous ICP pregnancies.
  • The peak bile-acid level in each pregnancy.
  • The gestational age at which the previous level rose.
  • Previous spontaneous or planned preterm birth.
  • Previous stillbirth or neonatal complications.
  • Whether the current pregnancy is singleton or multiple.
  • IVF or ovarian-stimulation history.
  • Current blood pressure.
  • Symptoms of pre-eclampsia.
  • Gestational diabetes.
  • Fetal growth and movement pattern.

The nutrition history includes:

  • Typical meal timing.
  • Long fasting intervals.
  • Fried and high-fat food intake.
  • Recent major dietary changes.
  • Vegetarian or non-vegetarian food pattern.
  • Protein intake.
  • Fibre intake and bowel pattern.
  • Hydration.
  • Herbal products, powders, teas or “detox” preparations.
  • Food intolerance after the itching began.
  • Whether itching or digestive discomfort changes after particular meals.
  • Changes in symptoms or bile acids after a structured dietary intervention.

For every bile-acid result, I review:

  • Date.
  • Gestational age.
  • Whether the sample was fasting or non-fasting.
  • The laboratory reference range.
  • Whether ursodeoxycholic acid had already been started.
  • The accompanying liver-function results.
  • The trend from previous samples.

A dietary history is reviewed as carefully as the medication history because both may influence maternal symptoms, metabolic health and interpretation of the biochemical trend.

One number tells us the concentration. The timeline tells us the disease.

What I Ask Patients to Bring

Please bring every available:

  • Bile-acid report.
  • Liver-function test.
  • Bilirubin report.
  • Coagulation report.
  • Blood-pressure record.
  • Glucose or gestational-diabetes report.
  • Ultrasound and growth-scan report.
  • CTG or fetal-monitoring report.
  • Previous ICP pregnancy records.
  • Previous delivery summary.
  • Neonatal discharge summary.
  • Liver or gallbladder ultrasound.
  • Hepatitis or autoimmune-liver test.
  • Complete medicine and supplement list.
  • A three-day food and meal-timing record, when possible.

A chronological list of bile-acid results with their gestational dates is particularly valuable.

The food record is not used to blame the patient.

It helps identify correctable patterns and allows the dietary plan to remain nutritionally adequate.

Missing documents should never prevent consultation.

The history can still be reconstructed from the information available.

Investigations

An Investigation Map — Not a Shopping List

The purpose of testing is to:

  • Confirm or challenge the diagnosis.
  • Identify the highest level of risk.
  • Exclude another liver disorder when indicated.
  • Decide how frequently testing should be repeated.
  • Plan the safest timing of birth.

1. Total Serum Bile Acids

This is the central laboratory test.

RCOG, SOGC and SOMANZ support a non-fasting or random threshold of:

19 µmol/L or more

in a pregnant woman with otherwise unexplained itching.

Other guidelines and laboratories may use different thresholds.

The result should therefore be interpreted using:

  • The clinical symptoms.
  • The pregnancy-specific reference range.
  • Whether the sample was fasting or non-fasting.
  • The method used by the laboratory.
  • Repeat measurements. [1,5,9]

2. Liver-Function Tests

These commonly include:

  • ALT.
  • AST.
  • Bilirubin.
  • GGT.
  • Albumin.
  • Alkaline phosphatase.

ALT and AST may be significantly raised in ICP.

They may also remain normal.

Bile acids may be abnormal even when routine liver enzymes are normal.

ALT and AST help assess maternal liver involvement.

They do not predict fetal risk as reliably as the peak bile-acid concentration.

3. Alkaline Phosphatase Requires Caution

Alkaline phosphatase naturally rises during pregnancy because the placenta produces it.

A raised alkaline phosphatase result alone is therefore not useful for diagnosing or grading ICP.

4. Bilirubin

Bilirubin is often normal.

Jaundice and substantial bilirubin elevation are less typical.

They require assessment for:

  • More severe cholestasis.
  • Biliary obstruction.
  • Viral hepatitis.
  • Another liver disorder.

5. Blood Count and Platelets

These may help identify:

  • Infection.
  • Anaemia.
  • Thrombocytopenia.
  • HELLP syndrome.
  • Another pregnancy complication.

6. Blood Pressure and Urine Protein

ICP is associated with an increased likelihood of pre-eclampsia.

Blood pressure and appropriate urine or laboratory assessment should not be overlooked.

7. Glucose Assessment

Gestational diabetes is more common in women with ICP.

Testing should follow the woman’s gestational age, previous results and risk factors.

8. Coagulation Testing

Most women with ICP do not develop a clotting disorder.

Prothrombin time or INR may be considered when there is:

  • Jaundice.
  • Severe or prolonged cholestasis.
  • Pale stools.
  • Suspected fat malabsorption.
  • Significant bleeding.
  • Another liver disorder.
  • Concern about vitamin K deficiency.

9. Liver and Gallbladder Imaging

An ultrasound of the liver or gallbladder is not required for every straightforward case.

It may be appropriate when there is:

  • Significant abdominal pain.
  • Jaundice.
  • Very early disease.
  • Severe biochemical abnormality.
  • Atypical symptoms.
  • Persistent abnormal tests after birth.
  • Previous gallstones or biliary disease.

10. Additional Liver Investigations

Selected women may require testing for:

  • Viral hepatitis.
  • Autoimmune liver disease.
  • Biliary obstruction.
  • Drug-induced liver injury.
  • Primary biliary cholangitis.
  • Primary sclerosing cholangitis.
  • Metabolic or genetic liver conditions.

These are not universal ICP panels.

They are selected according to the clinical presentation.

Reading the Numbers

Understanding the Bile Acid Report

What Does µmol/L Mean?

Bile acids are usually reported in:

Micromoles per litre, written as µmol/L.

The number measures the concentration in the maternal blood sample.

It does not directly measure the concentration around the baby.

It does not directly measure fetal wellbeing.

Fasting and Non-Fasting Results Are Not Automatically Equivalent

Bile acids normally rise after eating.

A fasting result may be lower than a non-fasting result obtained on the same day.

Modern risk-stratification guidance increasingly uses non-fasting measurements to avoid missing clinically important peaks.

Serial measurements should ideally be interpreted consistently.

A fasting result from one laboratory should not be compared casually with a non-fasting result from another without context.

The Laboratory Reference Range Matters

Different laboratories may use:

  • Different assay platforms.
  • Different upper limits.
  • Different fasting instructions.
  • Different reporting systems.

A result should not be interpreted using a copied internet threshold without checking the laboratory method.

Repeat Testing Is Essential

Bile acids may rise rapidly.

After diagnosis, blood tests are commonly repeated after approximately one week.

The frequency may increase according to:

  • Gestational age.
  • Disease severity.
  • Previous rate of rise.
  • Symptoms.
  • Other pregnancy complications.
  • Proximity to the planned delivery date.

The FIGO guideline advises at least weekly non-fasting bile-acid measurement from 32 weeks in confirmed ICP to identify clinically important rises.[4]

A Small Change May Not Be Clinically Significant

A change from 22 to 25 µmol/L is different from a rise from 25 to 105 µmol/L.

Interpretation should consider:

  • Laboratory variation.
  • Sample timing.
  • Treatment.
  • The overall trajectory.

A Falling Level Does Not Mean the Condition Has Disappeared

The level can fluctuate.

Risk stratification remains linked to the highest recorded concentration.

A woman whose level reached 110 µmol/L should not automatically be reclassified as mild because a later result is 32 µmol/L.

A fall after dietary treatment is clinically encouraging and may support continuation of the individualised plan.

It should be documented as a treatment response.

It must not be used to retrospectively delete a previous severe result or postpone an otherwise indicated delivery without complete clinical reassessment.

The ALT Is Not the Delivery Number

A very high ALT deserves maternal assessment.

It is not used in the same way as bile acids to estimate stillbirth risk.

A normal ALT does not make a bile-acid concentration of 120 µmol/L low risk.

Fetal Implications

What ICP Can Mean for the Baby

Most women with ICP have a healthy baby.

The purpose of specialist care is to identify pregnancies in which fetal risk has become meaningfully higher.

Spontaneous Preterm Birth

ICP is associated with an increased chance of labour beginning before 37 weeks.

The risk becomes more relevant when bile acids reach 40 µmol/L or more.

Planned Preterm or Early-Term Birth

Some babies are born early because the clinical team recommends delivery before the risk of continuing pregnancy rises further.

This is medically indicated birth.

Meconium-Stained Amniotic Fluid

The baby may pass meconium before birth.

The amniotic fluid may become green or brown.

The risk increases with more severe ICP.

Neonatal-Unit Admission

Admission may be required because of:

  • Prematurity.
  • Breathing difficulty.
  • Meconium exposure.
  • Another pregnancy complication.

Stillbirth

The risk is not equal at every bile-acid level.

The major increase occurs when the peak total bile-acid concentration reaches:

100 µmol/L or more

The risk rises particularly after approximately 35–36 weeks.

This is why delivery timing—not simply medication, diet or surveillance—forms the central fetal-protection strategy in severe ICP.[1–6]

Other Risk Factors Matter

The final risk may be higher when ICP occurs with:

  • Multiple pregnancy.
  • Pre-eclampsia.
  • Gestational diabetes.
  • Fetal growth restriction.
  • Previous ICP-related fetal loss.
  • Another maternal or fetal condition.
Monitoring

Fetal Surveillance

What Monitoring Can Do

Fetal surveillance can:

  • Assess the fetal heart-rate pattern at the time of testing.
  • Identify another obstetric concern.
  • Support decisions when fetal movements change.
  • Provide information when delivery would be considered for an abnormal result.

What Monitoring Cannot Do

A normal CTG cannot prove that the baby will remain safe until the next appointment.

A normal ultrasound cannot remove the risk associated with severe bile-acid elevation.

There is no antenatal test that reliably predicts every ICP-related stillbirth.

This is one reason severe ICP is not managed by repeated reassurance alone.

Monitoring observes the baby. It does not neutralise the bile-acid risk.

Where Guidelines Differ

SMFM suggests beginning antenatal fetal surveillance at a gestational age when the clinical team would act on an abnormal result, or at diagnosis when ICP is diagnosed later.

RCOG does not recommend additional growth scans solely because a woman has ICP.

SOMANZ similarly states that routine growth scans and CTG are not required in otherwise uncomplicated ICP.

These positions recognise the limitations of fetal testing and the importance of selecting surveillance according to the complete pregnancy picture.[1–3,9]

When Ultrasound Is Appropriate

An ultrasound may be required because of:

  • Reduced fetal movements.
  • Suspected growth restriction.
  • Multiple pregnancy.
  • Hypertension or pre-eclampsia.
  • Gestational diabetes.
  • Abnormal fundal-height measurement.
  • Another obstetric indication.

Fetal Movements

The mother should remain attentive to her baby’s usual movement pattern.

She should seek immediate maternity assessment if:

  • Movements reduce.
  • Movements stop.
  • The pattern changes significantly.
  • She feels that something is wrong.

She should not wait for:

  • The next clinic appointment.
  • The next bile-acid test.
  • The next scheduled CTG.
  • The itching to worsen.

A movement-counting application or home Doppler should not replace professional assessment.

Treatment

Treatment Must Follow the Purpose

IHCP treatment has more than one purpose.

One part aims to reduce itching and restore sleep.

Another addresses maternal nutrition, digestion, metabolic health and the biochemical pattern.

The final—and most important fetal-safety pathway—is based on repeat bile-acid measurement, recognition of additional pregnancy risks and appropriately timed birth.

In my practice, nutrition begins early.

It does not wait until every medicine has failed.

Treatment is divided into four groups.

Group 1
Nutrition-Led Maternal Management

Uses an individualised food plan to reduce avoidable dietary stress, maintain adequate pregnancy nutrition and support maternal metabolic and liver health.

Group 2
Treatment for Maternal Symptoms

Aims to reduce itching and improve sleep.

Group 3
Treatment of Associated Maternal Problems

Addresses vitamin deficiency, gestational diabetes, pre-eclampsia, gallbladder disease or another liver disorder when present.

Group 4
Fetal-Risk Reduction

Relies principally on the items listed below.

  • Correct disease classification.
  • Repeat bile-acid measurement.
  • Recognition of additional risk factors.
  • Attention to fetal movements.
  • Appropriately timed birth.
Nutrition

Dr Tania’s Nutrition-Led Approach

Nutrition Is Active Clinical Management

In my practice, food is not treated as a decorative lifestyle recommendation.

A detailed dietary history is taken alongside the history of itching, bile-acid values, liver enzymes, weight, digestion, glucose levels, medicines and pregnancy complications.

I have cared for many women whose itching and laboratory pattern improved substantially after a structured and individualised dietary programme.

In selected women, symptoms and biochemical results have remained controlled without requiring medication solely for symptom relief.

This clinical experience is important.

It must also be interpreted honestly.

An improvement in itching, ALT or bile acids does not prove that fetal risk has disappeared.

The highest bile-acid concentration reached during the pregnancy remains relevant when planning surveillance and birth.

Nutrition may improve the maternal and biochemical picture. It cannot, by itself, certify that the baby is safe.

What the Nutrition Plan Is Designed to Achieve

The plan is designed to:

  • Avoid prolonged fasting and irregular eating.
  • Maintain adequate pregnancy calories and protein.
  • Reduce heavy, deep-fried and repeatedly reheated foods.
  • Reduce excessive saturated fat and ultra-processed food.
  • Avoid large concentrated sugar loads when metabolic risk is present.
  • Use lighter cooking methods.
  • Increase suitable whole-food fibre gradually.
  • Maintain appropriate hydration.
  • Support regular bowel function.
  • Correct identified nutritional deficiencies safely.
  • Coordinate nutrition with gestational-diabetes or weight management when required.

The purpose is not to place every patient on the same printed “liver diet.”

The plan must consider:

  • Vegetarian or non-vegetarian food preferences.
  • Cultural and regional diet.
  • Gestational diabetes.
  • Maternal weight and pregnancy weight gain.
  • Nausea, vomiting or reflux.
  • Gallstones or fat intolerance.
  • Pale stools or suspected malabsorption.
  • Anaemia and protein intake.
  • Twin or higher-order pregnancy.
  • Food affordability and availability.

Fat Should Be Individualised—not Eliminated

Bile acids help digest fats and fat-soluble vitamins.

Some women notice that heavy or very fatty meals aggravate digestive discomfort.

This does not mean that every form of dietary fat should be removed.

Pregnancy still requires adequate energy and essential fatty acids.

Extreme fat restriction, crash dieting or an unbalanced liquid diet may create nutritional deficiency.

The amount, type and distribution of fat should therefore be adjusted individually rather than eliminated indiscriminately.

Fibre Has Biological Plausibility—but Is Not a Universal Prescription

Dietary fibre can influence bowel transit and the intestinal handling of bile acids.

A small randomised trial evaluated guar gum in women with ICP.

The trial involved only 39 women, and the subsequent Cochrane assessment found insufficient evidence to recommend guar gum as a routine treatment for all women with ICP.

Whole-food fibre may be used thoughtfully within a balanced plan.

Concentrated fibre preparations should not be self-prescribed as though they were proven fetal therapy.[11,12]

What I Do Not Recommend

I do not recommend:

  • Starvation or prolonged fasting.
  • Zero-fat diets.
  • Crash weight-loss diets.
  • Juice-only plans.
  • “Liver detox” programmes.
  • Unregulated herbal remedies.
  • High-dose supplements without a documented indication.
  • Abruptly stopping prescribed medicines.
  • Using a falling bile-acid result as permission to ignore the previous peak value.

Some herbal or “natural” preparations can themselves cause liver injury or interact with medicines.

When Nutrition Alone Is Not Enough

Nutrition should never delay:

  • Repeat bile-acid testing.
  • Investigation of jaundice or abdominal pain.
  • Assessment for pre-eclampsia.
  • Review of reduced fetal movements.
  • Treatment of significant sleep deprivation or itching.
  • Ursodeoxycholic acid when clinically indicated.
  • Specialist review of severe or early-onset disease.
  • Delivery recommended because of the peak bile-acid level or another maternal–fetal risk.

My approach is diet-led, not diet-blinded. Nutrition is used actively, while every fetal-safety threshold remains visible.

Why a General Website Cannot Prescribe One Meal Plan

The same food plan is not appropriate for:

  • A woman with bile acids of 24 µmol/L and normal glucose.
  • A woman with bile acids of 110 µmol/L and gestational diabetes.
  • A woman carrying twins.
  • A woman with gallstones.
  • A woman who is underweight or unable to eat adequately.
  • A woman with severe reflux, vomiting or anaemia.

The detailed meal strategy belongs in an individual consultation.

Separate educational articles may explain practical food choices, meal timing and sample Indian dietary patterns without suggesting that one menu can treat every pregnancy.

Ursodeoxycholic Acid

Ursodeoxycholic acid is commonly shortened to:

UDCA

SMFM recommends it as the first-line medicine for maternal symptoms of ICP.

It may:

  • Reduce itching modestly in some women.
  • Improve some liver-test results.
  • Possibly reduce spontaneous preterm birth in selected women, particularly when bile acids are 40 µmol/L or more.

It has not been proved to prevent every adverse fetal outcome.

It has not been proved to prevent stillbirth.

The large PITCHES randomised trial did not demonstrate a significant reduction in its primary composite perinatal outcome.

A subsequent individual-participant-data meta-analysis suggested a possible reduction in preterm birth in selected singleton pregnancies.

The evidence must therefore be explained accurately:

UDCA is principally used for maternal symptoms. It is not a substitute for bile-acid surveillance or appropriately timed birth. [3,4,7,8]

UDCA and nutrition should not be presented as competing philosophies.

In my practice, dietary management remains foundational.

UDCA is added when maternal symptoms, the biochemical pattern or individual clinical circumstances justify it.

Improvement after either intervention must still be interpreted against the highest bile-acid concentration reached during the pregnancy.

Dose and Monitoring

The preparation, dose and schedule should be prescribed individually.

The decision may consider:

  • Maternal weight.
  • Symptom severity.
  • Bile-acid level.
  • Treatment response.
  • Gastrointestinal side effects.
  • Other maternal medicines.

Patients should not alter the dose or stop treatment solely because one result improves.

Additional Measures for Itching

Supportive measures may include:

  • Cool baths or showers.
  • Loose cotton clothing.
  • Fragrance-free moisturisers.
  • Menthol-containing emollients.
  • Keeping the bedroom cool.
  • Antihistamines when clinically appropriate, particularly when they help sleep.

These measures may improve comfort.

They do not reduce the fetal risk associated with severe bile-acid elevation.

Vitamin K

Most women with ICP do not require vitamin K.

It may be considered in selected women when there is:

  • Abnormal coagulation.
  • Significant jaundice.
  • Fat malabsorption.
  • Pale stools.
  • Another reason to suspect deficiency.

Vitamin K should not be prescribed automatically to every woman with ICP.

Rifampicin

Rifampicin has been used in specialist settings for severe symptoms or biochemical disease that has not responded adequately to first-line management.

Evidence remains limited.

It requires specialist supervision because of:

  • Maternal monitoring.
  • Drug interactions.
  • Possible liver effects.
  • Neonatal and bleeding considerations.

It is not routine first-line treatment.

Treatments Not Recommended Routinely

The following should not be promoted as proven fetal- protection treatments:

  • Herbal liver cleanses.
  • Detox diets.
  • Cholestyramine for routine ICP management.
  • S-adenosyl methionine as standard treatment.
  • Dexamethasone as treatment for maternal cholestasis.
  • Repeated steroid courses intended to lower bile acids.
  • Aspirin solely because ICP is present.
  • Heparin solely because ICP is present.
  • Routine plasma exchange.
  • Routine early delivery before laboratory confirmation of elevated bile acids.
  • Home fetal-heart monitoring as reassurance.

Antenatal corticosteroids may still be recommended for fetal lung maturation when medically indicated preterm delivery is planned.

That is different from using steroids to treat ICP itself.

Delivery Planning

Timing of Birth

The Most Important Decision Is Not Always a Prescription

In severe ICP, fetal-risk reduction depends strongly on deciding when the baby may be safer outside the uterus than inside it.

The decision must balance:

  • Stillbirth risk.
  • Prematurity.
  • Peak bile-acid level.
  • Gestational age.
  • Other pregnancy complications.
  • Previous pregnancy history.
  • Local neonatal facilities.
  • The woman’s informed preference.

Why Guidelines Differ

International guidelines interpret the same evidence within different healthcare systems.

Their recommendations are close, but not identical.

This difference should be explained rather than hidden.

RCOG Approach for an Otherwise Uncomplicated Singleton Pregnancy

Peak Bile Acids 19–39 µmol/L

Planned birth by the estimated due date may be considered.

If there are no other risk factors, waiting for spontaneous labour may also be reasonable.

Peak Bile Acids 40–99 µmol/L

Planned birth at approximately:

38–39 weeks

may be recommended.

Peak Bile Acids 100 µmol/L or More

Planned birth at approximately:

35–36 weeks

may be recommended.[1,2]

SMFM and ACOG-Endorsed Approach

Bile Acids 100 µmol/L or More

Offer delivery at:

36 weeks 0 days

because the stillbirth risk rises substantially around this gestational age.

Bile Acids Below 100 µmol/L

Plan delivery within:

36 weeks 0 days to 39 weeks 0 days

The exact point within this range is individualised.

Women with levels below 40 µmol/L are generally placed toward the later end.

Women with levels of 40–99 µmol/L may be placed toward the earlier end.[3]

FIGO 2025 Approach

FIGO recommends:

  • Regular non-fasting bile-acid measurement.
  • Recognition that risk increases substantially at 100 µmol/L or more.
  • Consideration of elective delivery at approximately 35–36 weeks when the level reaches this severe range.[4]

Dr Tania’s Clinical Interpretation

The safest date should not be selected by copying one number from one chart.

The plan should account for:

  • The highest bile-acid concentration.
  • How rapidly the level rose.
  • The response to structured nutrition and treatment.
  • Current gestational age.
  • Previous ICP severity.
  • Previous ICP-related fetal loss.
  • Singleton or multiple pregnancy.
  • Pre-eclampsia.
  • Gestational diabetes.
  • Fetal growth.
  • Maternal liver function.
  • Severity of unrelenting symptoms.
  • Neonatal capability.
  • Risks of waiting compared with the risks of prematurity.

The delivery date is not chosen because the itching is unbearable alone. It is chosen after the maternal and fetal risks have been weighed together.

Delivery Before 35–36 Weeks

Earlier delivery may be considered in exceptional circumstances, including:

  • Another maternal or fetal indication.
  • Worsening liver disease.
  • Severe and unremitting symptoms despite treatment.
  • A previous ICP-related stillbirth before 36 weeks.
  • Non-reassuring fetal assessment.
  • Pre-eclampsia or another major complication.

This requires specialist decision-making.

Do Not Deliver Early for Itching Alone Without Confirmation

SMFM recommends against delivery before 37 weeks for a clinical diagnosis of ICP when elevated bile acids have not been laboratory-confirmed.

Persistent itching still deserves:

  • Repeat testing.
  • Assessment for another cause.
  • An individualised plan.

Antenatal Corticosteroids

When delivery before 37 weeks is planned and an appropriate course has not previously been given, antenatal corticosteroids may be recommended for fetal lung maturation.

Steroids do not treat or cure ICP.

Labour & Newborn

Labour and Newborn Care

Induction Does Not Mean Caesarean Birth

ICP alone does not require a planned caesarean birth.

Options may include:

  • Induction of labour.
  • Spontaneous labour when appropriate.
  • Planned caesarean for a separate obstetric indication.

The method of birth depends on:

  • Gestational age.
  • Cervical findings.
  • Fetal presentation.
  • Previous births.
  • Previous caesarean.
  • Fetal wellbeing.
  • Maternal preference.
  • Standard obstetric indications.

Fetal Monitoring During Labour

Continuous CTG may be advised when:

  • Bile acids reached 100 µmol/L or more.
  • There are additional pregnancy risks.
  • Labour is induced preterm.
  • Meconium is present.
  • Another clinical concern develops.

Meconium

The delivery team should be aware of the increased likelihood of meconium-stained fluid.

The newborn team should be available according to gestational age and clinical circumstances.

Neonatal Care

The baby may require:

  • Routine observation.
  • Assessment for prematurity.
  • Respiratory support.
  • Glucose monitoring.
  • Observation after meconium exposure.
  • Neonatal-unit admission when indicated.

Most babies do well.

Neonatal needs are more often related to:

  • Gestational age at birth.
  • Other pregnancy complications.
  • Meconium or breathing concerns.

Breastfeeding

ICP does not usually prevent breastfeeding.

The maternal medication plan should still be reviewed after delivery.

Preconception & Recurrence

The Next Pregnancy Begins Before the Positive Test

ICP usually improves after delivery.

Its history remains important.

Before Another Pregnancy

The plan may include:

  • Confirming that previous liver tests returned to normal.
  • Reviewing the peak bile-acid concentration.
  • Recording the gestational age at diagnosis.
  • Reviewing the timing and reason for delivery.
  • Identifying an underlying liver or gallbladder condition.
  • Reviewing medicines and contraception.
  • Arranging early-pregnancy baseline testing.

At the Beginning of the Next Pregnancy

RCOG advises checking liver-function tests and bile acids at the beginning of future pregnancies.

The woman should inform her clinician about the previous ICP even when she is not yet itching.

If Itching Returns

Bile acids and liver tests should be checked promptly.

A normal result early in pregnancy does not exclude recurrence later.

Recurrence

ICP commonly recurs.

The next pregnancy may:

  • Begin at a similar gestational stage.
  • Begin earlier.
  • Be milder.
  • Be more severe.

The previous pattern guides vigilance but does not perfectly predict the next pregnancy.

Contraception

After bile acids and liver tests have returned to normal, ICP does not automatically prohibit hormonal contraception.

If an oestrogen-containing contraceptive triggers itching or abnormal liver tests, medical review is required.

Long-Term Liver Health

Persistent or recurrent abnormal tests outside pregnancy may indicate an underlying liver or biliary condition.

This deserves assessment rather than being labelled indefinitely as pregnancy cholestasis.

After Birth: Confirm That It Has Ended

The itching usually improves rapidly after birth.

The laboratory results may take several weeks to normalise.

At approximately six weeks postpartum, the clinician should confirm:

  • The itching has resolved.
  • Liver-function tests have returned to normal.
  • Bile acids have returned to normal.

Further investigation or hepatology referral may be required when:

  • Itching persists.
  • Bile acids remain elevated.
  • Liver enzymes remain abnormal.
  • Jaundice persists.
  • Symptoms recur outside pregnancy.
  • There is a strong family or medical history.[2,10]

The diagnosis is completed only when the pregnancy- related abnormality resolves after birth.

Supportive Care Is Part of Medical Care

ICP can be exhausting.

The itching may prevent sleep for weeks.

Fear may increase each time the bile-acid report rises.

A woman may be repeatedly told:

  • “The scan is normal.”
  • “The CTG is normal.”
  • “Try not to worry.”
  • “It is only itching.”

That is not enough.

Supportive care includes:

  • A clear explanation of the current risk category.
  • A written schedule for repeat blood tests.
  • A direct route for reduced fetal movements.
  • Honest explanation of the limitations of CTG and ultrasound.
  • A provisional delivery window.
  • Review after every significant bile-acid rise.
  • Help with severe sleep disturbance.
  • Psychological support when anxiety becomes overwhelming.
  • Inclusion of the partner in major discussions.

Reassurance should come from a plan—not from pretending that the risk does not exist.

Hope Must Be Personal, Not Careless

Most women with ICP have a healthy baby.

The prognosis depends on:

  • The highest bile-acid concentration.
  • Gestational age when it rose.
  • Singleton or multiple pregnancy.
  • Other maternal complications.
  • Fetal condition.
  • Timing of birth.
  • Neonatal facilities.

When Bile Acids Remain Below 40 µmol/L

The stillbirth risk in an otherwise uncomplicated singleton pregnancy appears similar to background risk.

Repeat testing remains important because the level may rise.

When Bile Acids Reach 40–99 µmol/L

The risk of spontaneous preterm birth and meconium becomes more relevant.

A planned birth date is usually discussed before late term.

When Bile Acids Reach 100 µmol/L or More

The fetal-risk category changes.

Planned birth at approximately 35–36 weeks or 36 weeks— depending on the guideline and individual situation—is a central preventive strategy.

What Timely Care Can Achieve

Timely care can:

  • Introduce structured nutrition early.
  • Identify women whose symptoms and biochemical pattern respond to dietary management.
  • Maintain adequate pregnancy nutrition while reducing avoidable dietary stress.
  • Recognise promptly when nutrition and symptom treatment are no longer sufficient.
  • Detect biochemical progression.
  • Recognise severe disease.
  • Avoid relying on symptoms alone.
  • Avoid relying on liver enzymes alone.
  • Avoid waiting for a CTG to predict an unpredictable event.
  • Balance prematurity against stillbirth risk.
  • Plan birth in an appropriate hospital.
  • Prepare the neonatal team.

No clinician can guarantee the outcome.

The strongest care plan does not choose between nutrition and evidence-based obstetrics. It uses both.

FAQ

Frequently Asked Questions

Closing

A High Bile-Acid Result Is Not a Reason to Panic. It Is a Reason to Build a Complete Plan.

The itching raises suspicion.

The blood test confirms and grades the condition.

Nutrition becomes an active part of maternal management.

The response to diet and treatment is followed carefully.

The highest bile-acid level still helps define fetal risk.

A normal CTG does not erase severe biochemical disease.

A falling result does not erase a previous peak.

Ursodeoxycholic acid may improve symptoms.

Neither medicine nor diet replaces appropriately timed birth when the pregnancy enters a higher-risk category.

The objective is to enter the remainder of the pregnancy with:

  • The diagnosis confirmed accurately.
  • Other liver conditions excluded when necessary.
  • A personalised nutrition plan that remains adequate for pregnancy.
  • The highest bile-acid level identified.
  • Repeat testing scheduled.
  • Associated pregnancy risks assessed.
  • Fetal-movement guidance understood.
  • The limitations of surveillance explained.
  • A delivery window agreed before the risk rises.
  • Neonatal care available when early birth is required.
  • Postpartum resolution confirmed.
Schedule a High Bile Acids Consultation

Bring every bile-acid report. Leave with a nutrition, monitoring and delivery plan.

Schedule a High Bile Acids Consultation
Medical Disclaimer

Medical Disclaimer

This page provides general educational information about high bile acids and intrahepatic cholestasis of pregnancy.

It does not replace individual medical assessment, nutritional assessment, laboratory interpretation, diagnosis, treatment, fetal surveillance or delivery planning.

Bile-acid thresholds and delivery recommendations must be interpreted according to gestational age, peak concentration, laboratory method, singleton or multiple pregnancy, previous history and other maternal or fetal complications.

Reduced fetal movements, absent fetal movements, significant bleeding, contractions, fluid leakage, jaundice, dark urine, pale stools, severe abdominal pain, severe headache, visual disturbance, fainting, breathlessness or feeling seriously unwell may require urgent medical assessment.

Evidence Base

Evidence Base

  1. [1]Girling J, Knight CL, Chappell LC; Royal College of Obstetricians and Gynaecologists. Intrahepatic cholestasis of pregnancy: Green-top Guideline No. 43. BJOG. 2022;129(13):e95–e114. doi:10.1111/1471-0528.17206.
  2. [2]Royal College of Obstetricians and Gynaecologists. Intrahepatic Cholestasis of Pregnancy: Patient Information. First published 2022; updated April 2026.
  3. [3]Society for Maternal-Fetal Medicine. Consult Series No. 53: Intrahepatic cholestasis of pregnancy. American Journal of Obstetrics and Gynecology. 2021;224(2):B2–B9. Reaffirmed 2024. doi:10.1016/j.ajog.2020.11.002.
  4. [4]Nana M, Medina V, Maxwell C, et al. FIGO guideline on liver disease and pregnancy. International Journal of Gynecology & Obstetrics. 2025;170(1):28–48. doi:10.1002/ijgo.70161.
  5. [5]Hobson SR, Cohen ER, Gandhi S, et al. Guideline No. 452: Diagnosis and Management of Intrahepatic Cholestasis of Pregnancy. Journal of Obstetrics and Gynaecology Canada. 2024;46(8):102618. doi:10.1016/j.jogc.2024.102618.
  6. [6]Ovadia C, Seed PT, Sklavounos A, et al. Association of adverse perinatal outcomes of intrahepatic cholestasis of pregnancy with biochemical markers: aggregate and individual-patient-data meta-analyses. The Lancet. 2019;393(10174):899–909. doi:10.1016/S0140-6736(18)31877-4.
  7. [7]Chappell LC, Bell JL, Smith A, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy: the PITCHES randomised controlled trial. The Lancet. 2019;394(10201):849–860. doi:10.1016/S0140-6736(19)31270-X.
  8. [8]Ovadia C, Sajous J, Seed PT, et al. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a systematic review and individual-participant-data meta-analysis. The Lancet Gastroenterology & Hepatology. 2021;6(7):547–558. doi:10.1016/S2468-1253(21)00074-1.
  9. [9]Hague WM, Briley A, Callaway L, et al. Intrahepatic cholestasis of pregnancy—diagnosis and management: a SOMANZ consensus statement executive summary. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2023;63(5):656–665. doi:10.1111/ajo.13719.
  10. [10]European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of liver diseases in pregnancy. Journal of Hepatology. 2023;79(3):768–828. doi:10.1016/j.jhep.2023.03.006.
  11. [11]Riikonen S, Savonius H, Gylling H, Nikkilä K, Tuomi AM, Miettinen TA. Oral guar gum, a gel-forming dietary fiber, relieves pruritus in intrahepatic cholestasis of pregnancy. Acta Obstetricia et Gynecologica Scandinavica. 2000;79(4):260–264. PMID: 10746839.
  12. [12]Walker KF, Chappell LC, Hague WM, Middleton P, Thornton JG. Pharmacological interventions for treating intrahepatic cholestasis of pregnancy. Cochrane Database of Systematic Reviews. 2020;7:CD000493. doi:10.1002/14651858.CD000493.pub3.